Search Results 1921-1930 of 17056 for monoclonal antibody

1. Neurology - Clinical trials

   The purpose of this study is to determine the prevalence, diagnostic accuracy and predictors of antinueronal antibody positivity in serum and cerebrospinal ...

2. Fungal Infections Clinical Trials - Mayo Clinic Research

   The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive ...

3. Mayo Clinic scientists pioneer immunotherapy technique for autoimmune diseases

   Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.

4. A Study to Evaluate AL102 to Treat Patients with Progressing Desmoid Tumors - Mayo Clinic

   Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or ...

5. A Randomized Multicenter Study for Isolated Skin Vasculitis - Mayo Clinic

   ... antibody (ANCA) by immunofluorescence or ELISA. Hypocomplementemic urticarial vasculitis, cryoglobulinemic vasculitis, and other known secondary skin ...

6. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer - Mayo Clinic

   Pre-existing systemic autoimmune or antibody-mediated diseases or immune deficiency diseases. Central nervous system (CNS) metastases. Serious, non-healing ...

7. A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors

   Has received systemic anticancer medication ≤ 4 weeks (6 weeks of nitrosourea, mitomycin-c, or antibodies) before starting study drug or has not recovered ...

8. Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies - Mayo Clinic

   History of documented allergic reactions or acute hypersensitivity reaction attributed to treatment with antibody therapies in general, or to agents ...

9. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors - Mayo Clinic

   ... antibodies (for Sub-Part 1C) * Unstable or deteriorating cardiovascular disease within the previous 6 months * Any major surgery within 4 weeks of study ...

10. BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO) - Mayo Clinic

    - Active infection including hepatitis B (known positive HBV/HBsAg result), HCV, or HIV 1/2 (positive HIV) antibodies. - Current or prior use of ...